A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with anthracyclines and taxanes. This study aimed to evaluate...
Guardado en:
Autores principales: | Jiaojiao Suo, Xiaorong Zhong, Ping He, Hong Zheng, Tinglun Tian, Xi Yan, Ting Luo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ff823bd8ac78446d8430437deb181d7f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Hélène Bellio, et al.
Publicado: (2021) -
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
por: Ko AH
Publicado: (2016) -
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
por: Se Jun Park, et al.
Publicado: (2021) -
pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment
por: Shirleide Santos Nunes, et al.
Publicado: (2021) -
Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Li-Yan Zhou, et al.
Publicado: (2015)